334477-68-8

Basic information

• Product Name: 3-(4-fluoro-2-methylphenyl)-piperazin-2-one
• Synonyms: 3-(4-fluoro-2-methylphenyl)-piperazin-2-one
• CAS NO: 334477-68-8
• Molecular Weight: 208.235
• Mol File: 334477-68-8.mol

Chemical Properties

• Boiling Point: 407.2±45.0 °C(Predicted)
• Density: 1.158±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 3-(4-fluoro-2-methylphenyl)-piperazin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-fluoro-2-methylphenyl)-piperazin-2-one(334477-68-8)
• EPA Substance Registry System: 3-(4-fluoro-2-methylphenyl)-piperazin-2-one(334477-68-8)

Safety Data

• Hazardous Substances Data: 334477-68-8(Hazardous Substances Data)

Upstream product

• 30897-90-6 (2-methyl-4-fluorophenyl)magnesium bromide 
• 334477-07-5 (4-fluoro-2-methylphenyl)oxoacetic acid methyl ester 
• 452-63-1 2-Bromo-5-fluorotoluene 
• 334477-08-6 3-(4-fluoro-2-methylphenyl)-5,6-dihydro-1H-pyrazin-2-one 

Downstream Products

• 334477-72-4 (3S)-3-(4-fluoro-2-methylphenyl)-2-piperazinone (S)-mandelate 
• 334476-68-5 2-(S)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide 
• 334477-18-8 (+)-(S)-3-(4-fluoro-2-methylphenyl)-piperazin-2-one 
• 1153574-57-2 (-)-(R)-3-(4-fluoro-2-methylphenyl)-piperazin-2-one 

Relevant articles and documents

Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis- trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor

In an effort to discover novel druglike NK1 receptor antagonists a new series of suitably substituted C-phenylpiperazine derivatives was identified by an appropriate chemical exploration of related N-phenylpiperazine analogues, with the specifi

Synthesis of the NK1 receptor antagonist GW597599. Part 3: Development of a scalable route to a key chirally pure arylpiperazine urea, a happy end

GW597599 1 is a novel NK-1 antagonist currently under investigation for the treatment of central nervous system disorders and emesis. The initial chemical development synthetic route, derived from the one used by medicinal chemistry, involved several haza

Synthesis of the NK1 receptor antagonist GW597599. Part 1: development of a scalable route to a key chirally pure arylpiperazine

GW5975991 is a novel NK-1 antagonist currently under investigation for the treatment of CNS disorders and emesis. The initial synthetic route devised from the medicinal chemistry one, used several hazardous reagents, gave low yields, and produced high lev